choroidal neovascularization,proliferative diabetic retinopathy, central retinal vein occlusion neovascular glaucoma
Conditions
Interventions
1,The administration of bevacizumab 1.25mg to target patient. 2,Compared a the administration Day1,Day7,Day28and prior to administration. -Visual acuity -Intra ocular pressure -Evaluation of new b
Sponsors
Nagasaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Choroidal neovascularization -Patient there is no adaptation of photodynamic therapy. -Patients Bevacizumab administered is determined to more high effective 2.Proliferative diabetic retinopathy Central retinal vein occulusion -Patients improved even after the existing treatment or surgery therapy is not seen. 3.Neovascular glaucoma -The patient after the fallpan-retinal photocoagulation, the intraocular pressure even using the Ocular hypotensive agents does not.
Exclusion criteria
Exclusion criteria: Patients physician has judged inappropriate and comprehensive evaluation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual acuity | — |
Secondary
| Measure | Time frame |
|---|---|
| Intra ocular pressure The degree of ischemia with fluorescein angiography Central retinal thickness | — |
Countries
Japan
Contacts
Public ContactMakiko Mtumoto
Nagasaki University Hospital Department of ophthalmology
Outcome results
None listed